Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Lofexidine - Britannia Pharmaceuticals

Drug Profile

Lofexidine - Britannia Pharmaceuticals

Alternative Names: BA-168; BritLofex; Lofexidine hydrochloride; LUCEMYRA; MDL-14042; MDL-14042A; RMI-14042A

Latest Information Update: 04 Sep 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Britannia Pharmaceuticals
  • Developer Britannia Pharmaceuticals; Salix Pharmaceuticals; US WorldMeds
  • Class Antihypertensives; Chlorobenzenes; Imidazolines; Phenyl ethers; Small molecules
  • Mechanism of Action Alpha 2 adrenergic receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes - Opioid abuse

Highest Development Phases

  • Marketed Opioid abuse

Most Recent Events

  • 02 Aug 2019 US WorldMeds initiates enrolment in the phase II TAPER trial for Opioid abuse in USA (PO) (NCT04070157)
  • 06 Aug 2018 Launched for Opioid abuse in USA (PO)
  • 26 Jun 2018 Lofexidine is expected to be commercially available in USA in August 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top